Methods of treatment using anti-IL-17A/IL-17F cross-reactive antibodies
US8771697B2 · kind B2 · utility
6Cited by
55References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2012 |
| Grant date | Jul 8, 2014 |
| Priority date | — |
| Expiry date | Jun 8, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.